Genmab A/S (NASDAQ:GMAB) Price Target Raised to $42.00

Дата публикации: 10-08-2026 05:48:47

Genmab A/S (NASDAQ:GMAB – Free Report) had its target price hoisted by Guggenheim from $40.00 to $42.00 in a report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock. Other analysts have also recently issued reports about the company. TD Cowen raised Genmab A/S from a “hold” rating to a […]

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $42.00	0	11.84	10-08-2026
2	Genpact (NYSE:G) Price Target Raised to $45.00	0	14.26	10-08-2026
3	Guggenheim Cuts Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $23.00	0	9.15	10-08-2026
4	Akamai Technologies (NASDAQ:AKAM) Price Target Raised to $190.00	0	12.21	10-08-2026
5	PubMatic (NASDAQ:PUBM) Price Target Raised to $23.00	0	11.49	10-08-2026
6	AMN Healthcare Services (NYSE:AMN) Price Target Raised to $35.00	0	10.79	10-08-2026
7	BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $60.00	0	12.21	10-08-2026
8	Replimune Group (NASDAQ:REPL) Price Target Raised to $20.00	0	13.83	10-08-2026
9	Avient (NYSE:AVNT) Price Target Raised to $48.00	0	14.17	10-08-2026
10	Celldex Therapeutics (NASDAQ:CLDX) Price Target Raised to $53.00	0	11.84	10-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.76. Источник: www.americanbankingnews.com.